These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

304 related items for PubMed ID: 6766909

  • 1. Altering the course of cataracts in diabetic rats.
    Fukushi S, Merola LO, Kinoshita JH.
    Invest Ophthalmol Vis Sci; 1980 Mar; 19(3):313-5. PubMed ID: 6766909
    [Abstract] [Full Text] [Related]

  • 2. Nonosmotic diabetic cataracts.
    Malone JI, Lowitt S, Cook WR.
    Pediatr Res; 1990 Mar; 27(3):293-6. PubMed ID: 2138728
    [Abstract] [Full Text] [Related]

  • 3. Implications of aldose reductase in cataracts in human diabetes.
    Varma SD, Schocket SS, Richards RD.
    Invest Ophthalmol Vis Sci; 1979 Mar; 18(3):237-41. PubMed ID: 106020
    [Abstract] [Full Text] [Related]

  • 4. Effect of instillation of aldose reductase inhibitor FR74366 on diabetic cataract.
    Ao S, Kikuchi C, Ono T, Notsu Y.
    Invest Ophthalmol Vis Sci; 1991 Nov; 32(12):3078-83. PubMed ID: 1834606
    [Abstract] [Full Text] [Related]

  • 5. Diabetic cataracts in animal models: prevention and reversibility with aldose reductase inhibitors.
    Kador PF, Akagi Y, Kinoshita JH.
    Diabet Med; 1985 May; 2(3):194-6. PubMed ID: 2952419
    [No Abstract] [Full Text] [Related]

  • 6. [Effects of M79175, an aldose reductase inhibitor, on experimental sugar cataracts].
    Ono H, Nozawa Y, Hayano S.
    Nippon Ganka Gakkai Zasshi; 1982 May; 86(9):1343-50. PubMed ID: 6818854
    [No Abstract] [Full Text] [Related]

  • 7. Reversal of diabetic cataract by sorbinil, an aldose reductase inhibitor.
    Beyer-Mears A, Cruz E.
    Diabetes; 1985 Jan; 34(1):15-21. PubMed ID: 3917257
    [Abstract] [Full Text] [Related]

  • 8. High-performance liquid chromatographic analysis of glucose, fructose, sorbitol and low levels of the aldose reductase inhibitor sorbinil in human lens and plasma.
    Lloyd P, Crabbe MJ.
    J Chromatogr; 1985 Oct 11; 343(2):402-6. PubMed ID: 3934205
    [No Abstract] [Full Text] [Related]

  • 9. Galactose cataract prevention with sorbinil, an aldose reductase inhibitor: a light microscopic study.
    Datiles M, Fukui H, Kuwabara T, Kinoshita JH.
    Invest Ophthalmol Vis Sci; 1982 Feb 11; 22(2):174-9. PubMed ID: 6799419
    [Abstract] [Full Text] [Related]

  • 10. Immunohistochemical localization for aldose reductase in diabetic lenses.
    Akagi Y, Kador PF, Kinoshita JH.
    Invest Ophthalmol Vis Sci; 1987 Jan 11; 28(1):163-7. PubMed ID: 3100473
    [Abstract] [Full Text] [Related]

  • 11. Diabetic complications in lens and nerve and their prevention by sulindac or sorbinil: two novel aldose reductase inhibitors.
    Jacobson M, Sharma YR, Cotlier E, Hollander JD.
    Invest Ophthalmol Vis Sci; 1983 Oct 11; 24(10):1426-9. PubMed ID: 6413448
    [Abstract] [Full Text] [Related]

  • 12. The effect of ponalrestat on sorbitol levels in the lens of obese and diabetic mice.
    Vicario PP, Slater EE, Saperstein R.
    Biochem Int; 1989 Sep 11; 19(3):553-61. PubMed ID: 2510726
    [Abstract] [Full Text] [Related]

  • 13. The sorbitol pathway in the human lens: aldose reductase and polyol dehydrogenase.
    Jedziniak JA, Chylack LT, Cheng HM, Gillis MK, Kalustian AA, Tung WH.
    Invest Ophthalmol Vis Sci; 1981 Mar 11; 20(3):314-26. PubMed ID: 6782033
    [Abstract] [Full Text] [Related]

  • 14. Effects of a new aldose reductase inhibitor on diabetic complications in rats.
    Gervasi GB, Bartoli C, Catalani R, Farina C, Carpita G, Caccia G, Ammannati P.
    Arzneimittelforschung; 1991 Nov 11; 41(11):1160-3. PubMed ID: 1810261
    [Abstract] [Full Text] [Related]

  • 15. [Aldose-reductase inhibitors and cataract formation (author's transl)].
    Keller G, Leuenberger PM.
    Klin Monbl Augenheilkd; 1980 Apr 11; 176(4):514-5. PubMed ID: 6775130
    [Abstract] [Full Text] [Related]

  • 16. Effects of aldose reductase inhibitor on retinal microangiopathy in streptozotocin-diabetic rats.
    Kojima K, Matsubara H, Harada T, Mizuno K, Suzuki M, Hotta N, Kakuta H, Sakamoto N.
    Jpn J Ophthalmol; 1985 Apr 11; 29(1):99-109. PubMed ID: 3159927
    [Abstract] [Full Text] [Related]

  • 17. Aldose reductase and the etiology of diabetic cataracts.
    Varma SD.
    Curr Top Eye Res; 1980 Apr 11; 3():91-155. PubMed ID: 6807610
    [No Abstract] [Full Text] [Related]

  • 18. The effect of aldose reductase and its inhibition on sugar cataract formation.
    Kador PF, Akagi Y, Kinoshita JH.
    Metabolism; 1986 Apr 11; 35(4 Suppl 1):15-9. PubMed ID: 3083204
    [Abstract] [Full Text] [Related]

  • 19. Properties of ICI 128,436, a novel aldose reductase inhibitor, and its effects on diabetic complications in the rat.
    Stribling D, Mirrlees DJ, Harrison HE, Earl DC.
    Metabolism; 1985 Apr 11; 34(4):336-44. PubMed ID: 3920474
    [Abstract] [Full Text] [Related]

  • 20. Raman spectroscopic study of the effect of aldose reductase inhibitor on experimental diabetic cataract.
    Nozawa H, Yaginuma T, Mizuno A.
    Nippon Ganka Gakkai Zasshi; 1988 Jan 11; 92(1):194-201. PubMed ID: 3133929
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.